LYEL: Pivotal cell therapy trials show strong efficacy, with major data and BLA milestones ahead
Two pivotal cell therapy programs are advancing, with LYL273 showing strong response rates and safety improvements in metastatic colorectal cancer and ronde-cel leading in large B-cell lymphoma. Major data updates and a BLA submission are expected within the next year, positioning the company for c…